TUCSON   520.748.4400

David A. Wiersma

Senior Associate

Wiersma manages development and prosecution of RCT’s pharmaceutical and biologics patent estate, evaluates intellectual property for RCT investment opportunities, and manages a portfolio of commercialized technologies. During his career at RCT, Wiersma has participated in the commercialization of the cisplatinum anticancer agents Platinol® and Paraplatin®, cationic radiopharmaceuticals (Cardiolite®, Myoview™) and the PSA blood test for prostate cancer. His scientific areas of focus at RCT are biologics, diagnostics, oncology, and metabolic disease.

Professional Experience

  • Research Corporation Technologies
    Senior Associate, 1999-present
    Director, Alerion Biomedical Inc., 2004-2007
    Director, MetaProbe Inc., 1997-2004
    Manager, MetaProbe LLC, 1997
    Science Advisory Board, Sertoli Technologies Inc., 1996-2006
    Associate, Life Sciences, 1987-1999
    Registered U.S. Patent Agent, 1985-present
    Research Corporation, 1984-1987
  • The University of Arizona
    Research Associate, College of Pharmacy, 1982-2006
  • Michigan Drug Detection Center
    Laboratory Technologist, Grand Rapids, Michigan, 1975-1977

Education

  • Michigan State University
    Ph.D., Pharmacology
  • Calvin College
    B.S., Biology-Chemistry

Contact

DWiersma@RCTech.com

Assistant: Andrea Isner
(520) 748-4468

General: (520) 748-4400